Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial

Open access
I-SPY2 Trial Consortium, Yee, Douglas, DeMichele, Angela M., Yau, Christina, Isaacs, Claudine, Symmans, W. Fraser, Albain, Kathy S., Chen, Yunn-Yi, Krings, Gregor, Wei, Shi, Harada, Shuko, Datnow, Brian, Fadare, Oluwole, Klein, Molly, Pambuccian, Stefan, Chen, Beiyun, Adamson, Kathi, Sams, Sharon, Mhawech-Fauceglia, Paulette, Magliocco, Anthony, Feldman, Mike, Rendi, Mara, Sattar, Husain, Zeck, Jay, Ocal, Idris T., Tawfik, Ossama, LeBeau, Lauren Grasso, Sahoo, Sunati, Vinh, Tuyethoa, Chien, A. Jo, Forero-Torres, Andres, Stringer-Reasor, Erica, Wallace, Anne M., Pusztai, Lajos, Boughey, Judy C., Ellis, Erin D., Elias, Anthony D., Lu, Janice, Lang, Julie E., Han, Hyo S., Clark, Amy S., Nanda, Rita, Northfelt, Donald W., Khan, Qamar J., Viscusi, Rebecca K., Euhus, David M., Edmiston, Kirsten K., Chui, Stephen Y., Kemmer, Kathleen, Park, John W., Liu, Minetta C., Olopade, Olufunmilayo, Leyland-Jones, Brian, Tripathy, Debasish, Moulder, Stacy L., Rugo, Hope S., Schwab, Richard, Lo, Shelly, Helsten, Teresa, Beckwith, Heather, Haugen, Patricia, Hylton, Nola M., van’t Veer, Laura J., Perlmutter, Jane, Melisko, Michelle E., Wilson, Amy, Peterson, Garry, Asare, Adam L., Buxton, Meredith B., Paoloni, Melissa, Clennell, Julia L., Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Matthews, Jeffrey B., Asare, Smita M., Sanil, Ashish, Berry, Scott M., Esserman, Laura J., Berry, Donald A.·2020·JAMA Oncology

Abstract

Importance: Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. Objective: To evaluate the association of pCR with event-free survival (EFS) and pCR with distant recurrence-free survival (DRFS) in subpopulations of women with high-risk operable breast cancer treated with standard therapy or one of several novel agents. Design, Setting, and Participants: Multicenter platform trial of women with operable clinical stage 2 or 3 breast cancer with no prior surgery or systemic therapy for breast cancer; primary tumors were 2.5 cm or larger. Women with tumors that were ERBB2 negative/hormone receptor (HR) positive with low 70-gene assay score were excluded. Participants were adaptively randomized to one of several different investigational regimens or control therapy within molecular subtypes from March 2010 through 2016. The analysis included participants with follow-up data available as of February 26, 2019. Interventions: Standard-of-care neoadjuvant therapy consisting of taxane treatment with or without (as control) one of several investigational agents or combinations followed by doxorubicin and cyclophosphamide. Main Outcomes and Measures: Pathologic complete response and 3-year EFS and DRFS. Results: Of the 950 participants (median [range] age, 49 [23-77] years), 330 (34.7%) achieved pCR. Three-year EFS and DRFS for patients who achieved pCR were both 95%. Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. Conclusions and Relevance: The 3-year outcomes from the I-SPY2 trial show that, regardless of subtype and/or treatment regimen, including 9 novel therapeutic combinations, achieving pCR after neoadjuvant therapy implies approximately an 80% reduction in recurrence rate. The goal of the I-SPY2 trial is to rapidly identify investigational therapies that may improve pCR when validated in a phase 3 confirmatory trial. Whether pCR is a validated surrogate in the sense that a therapy that improves pCR rate can be assumed to also improve long-term outcome requires further study. Trial Registration: ClinicalTrials.gov Identifier: NCT01042379.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2020.2535

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 221

Metadata

Authors
I-SPY2 Trial Consortium, Yee, D., DeMichele, A. M., Yau, C., Isaacs, C., Symmans, W. F., Albain, K. S., Chen, Y.-Y., Krings, G., Wei, S., Harada, S., Datnow, B., Fadare, O., Klein, M., Pambuccian, S., Chen, B., Adamson, K., Sams, S., Mhawech-Fauceglia, P., Magliocco, A., Feldman, M., Rendi, M., Sattar, H., Zeck, J., Ocal, I. T., Tawfik, O., LeBeau, L. G., Sahoo, S., Vinh, T., Chien, A. J., Forero-Torres, A., Stringer-Reasor, E., Wallace, A. M., Pusztai, L., Boughey, J. C., Ellis, E. D., Elias, A. D., Lu, J., Lang, J. E., Han, H. S., Clark, A. S., Nanda, R., Northfelt, D. W., Khan, Q. J., Viscusi, R. K., Euhus, D. M., Edmiston, K. K., Chui, S. Y., Kemmer, K., Park, J. W., Liu, M. C., Olopade, O., Leyland-Jones, B., Tripathy, D., Moulder, S. L., Rugo, H. S., Schwab, R., Lo, S., Helsten, T., Beckwith, H., Haugen, P., Hylton, N. M., van’t Veer, L. J., Perlmutter, J., Melisko, M. E., Wilson, A., Peterson, G., Asare, A. L., Buxton, M. B., Paoloni, M., Clennell, J. L., Hirst, G. L., Singhrao, R., Steeg, K., Matthews, J. B., Asare, S. M., Sanil, A., Berry, S. M., Esserman, L. J., & Berry, D. A.
Venue
JAMA Oncology
Published
2020-09-01
Volume
6
Issue
9
Pages
1355
ISSN
2374-2437 (ISSN-L)
OpenAlex
W3044857394
Cited by
221
References
3
FWCI
8.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2020.2535
The paper
I-SPY2 Trial Consortium, Yee, D., DeMichele, A. M., Yau, C., Isaacs, C., Symmans, W. F., Albain, K. S., Chen, Y.-Y., Krings, G., Wei, S., Harada, S., Datnow, B., Fadare, O., Klein, M., Pambuccian, S., Chen, B., Adamson, K., Sams, S., Mhawech-Fauceglia, P., . . . Berry, D. A. (2020). Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2020.2535

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.